Trials / NCT06460844
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Underway, not enrolling Phase 1 Optogenetics, Gene therapy
- Sponsor
- Ray Therapeutics, Inc.
- Treatment
- RTx-015
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa, Choroideremia
- Ages
- 18 Years to no upper limit
- Enrollment
- 10 participants
- Started
- 2024-08-27
- Main results expected
- 2030-10
- Results posted
- Not yet
- Record last updated
- 2026-02-20
What the study is testing
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Where it runs
United States (4)
- Retina Vitreous Associates Medical Group, Beverly Hills, California
- UCI Alpha Clinic, Orange, California
- UPMC Vision Institute, Pittsburgh, Pennsylvania
- Retina Consultants of Texas Research Centers, Bellaire, Texas